Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTK7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTK7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PTK7 Products |
| Gene Delivery | PTK7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PTK7 Products |
| Benchmark Ab | Anti-PTK7 (Sequence of Cofetuzumab) Recombinant positive control. |
View PTK7 Products |
| Validator | PTK7 siRNA Set For knockdown verification. |
View PTK7 Products |
| Related Target A | WNT5A Primary ligand in the non-canonical Wnt signaling pathway. |
View WNT5A Products |
| Related Target B | ROR2 Co-receptor in the Wnt/PCP pathway, frequently co-expressed in tumors. |
View ROR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization Assays | HEK293 Expressed (Native Glycosylation) ECD-Fc for accurate receptor-mediated endocytosis modeling. |
| Cross-species Tox Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks and target validation. |
Live PTK7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTK7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs). As an evolutionarily conserved pseudokinase highly expressed in solid tumors (NSCLC, TNBC, melanoma) and rapidly internalized upon antibody binding, PTK7 is an ideal payload delivery vehicle. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimized payload chemistries and dual-targeting bispecifics to overcome tumor heterogeneity and minimize off-target toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Genmab/BioNTech, Daiichi Sankyo, AbbVie | Solid Tumors (NSCLC, TNBC, Ovarian) | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific | Early-stage Biotechs | Refractory Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| CAR-T / Cell Therapy | Academic/Emerging Biotechs | Advanced Melanoma, Colorectal Cancer | Antigen Density Profiling (Need Native HEK293 Proteins) |